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Abstract
Background: The use of stem cells from adipose tissue or adipose-derived stem cells (ASCs) in regenerative
medicine could be an interesting alternative to bone marrow stem cells because they are easily accessible and
available in large quantities. The aim of this study was to evaluate the potential effect of ASCs on the healing of
12 mm diameter-excisional wounds (around 110 mm2) in nude mice.
Methods: Thirty nude mice underwent surgery to create one 12-mm excisional wound per mouse (spontaneous
healing, n = 6; Cytocare® 532, n = 12; ASCs, n = 12). The Galiano wound model was chosen to avoid shrinkage and
thus slow the spontaneous healing (SH) of mouse skin, making it closer to the physiology of human skin healing.
Transparent dressings were used to enable daily healing time measurements to be taken. Immunohistochemistry,
histological and blood perfusion analysis were carried out on the healed skin.
Results: The in vivo results showed the effectiveness of using ASCs on reducing the time needed for complete
healing to 21.2 days for SH, 17.4 days for vehicle alone (Cytocare® 532) and 14.6 days with the addition of ASCs
(p < 0.001). Moreover, cutaneous perfusion of the healed wound was significantly improved in ASC-treated mice
compared to SH group, as shown by laser Doppler flowmetry and the quantitation of blood vessels using
immunohistochemistry of αsmooth muscle actin.
Conclusions: The tolerance and efficacy of cryopreserved ASCs to accelerate the complete closure of the
wound by increasing the maturation of the skin and its blood perfusion, shows their therapeutic benefit in
the wound healing context.
Keywords: Adipose-derived stem cells, Cutaneous wound healing, Skin blood perfusion, Vehicle
Background
Wounds are challenges that are often encountered in
plastic and reconstructive surgery [1]. Indeed, healing is
compromised in many situations such as diabetes,
chronic renal failure, and irradiation, but also with age
[2]. So, faced with an aging population today, chronic
wounds are a real public health problem [3, 4]. The main
aims of treatment are the rapid closure of the wound to
restore the barrier function of the skin and prevent in-
fection, the suppression of pain, and functional recovery,
allowing a rapid return to a normal social and profes-
sional life, and equally important, obtaining a satisfac-
tory result from an aesthetic point of view.
Many strategies have been tried with varying success in
the treatment of chronic wounds: the injection of growth
factors [5–7], grafts of temporary skin substitutes (porcine
xenograft, synthetic membranes, atelocollagen matrix, and
allogenic substitutes) [7, 8], or permanent ones (epidermal
substitutes and cultured dermis) [9, 10]. However, large
wounds, under adverse local and systemic conditions (low
vascularization, metabolic disease, etc), respond poorly to
these treatments and frequently reopen.
* Correspondence: jonathan.rodriguez@chu-lyon.fr
Odile Damour and Ali Mojallal are co-last authors.
1Banque de tissus et cellules, Laboratoire des substituts cutanés, Hôpital
Edouard Herriot, Hospices Civils de Lyon, 5, place d’Arsonval, Pavillon i, 69437
Lyon, France
2INSERM U1060, CarMeN laboratory, Oullins, France
Full list of author information is available at the end of the article
© 2015 Rodriguez et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Rodriguez et al. Stem Cell Research & Therapy  (2015) 6:241 
DOI 10.1186/s13287-015-0238-3
Over the last decade, plastic surgery has been marked
by the introduction of many reconstructive therapies
based on the use of stem cells. These are undifferenti-
ated cells with self-renewing properties that are able to
divide and generate specialized cells, including skin cells
[11]. From this point of view, the stromal vascular frac-
tion (SVF) of adipose tissue has been shown to be very
effective in experimental healing models. The suggested
mechanism of action is the increased cell proliferation
and vascularization, modulation of inflammation, and in-
creased fibroblastic activity of adipose-derived stem cells
(ASCs) present in the SVF [12]. ASCs share many prop-
erties with mesenchymal stem cells from bone marrow
and cord blood, including their multipotency and, in
particular, their potential to differentiate into endothelial
cells and fibroblasts [11]. However, SVF is a heteroge-
neous cell suspension containing a small percentage
(between 1 and 3 %) of ASCs [13, 14]. Today, using
protocols for the isolation and in vitro expansion of
ASCs, it is easily possible to obtain a homogeneous
therapeutic product containing more than 90 % ASCs
[15]. In addition, the ASC amplification phase requires
their extraction from only a small volume of lipoaspirate,
which is particularly advantageous in frail, elderly or
diabetic patients. Finally, the possibility of freezing ASCs
pending their therapeutic use, offers the opportunity
to 1) perform all the necessary safety checks before
releasing the therapy product and 2) repeat the treat-
ment if necessary.
Of the preclinical trials performed so far using ASCs,
most have been performed on rodents [16–28] and only a
few on porcine [29–33] and rabbit [34, 35] models, prob-
ably due to the lack of availability, high cost, management
difficulty and the strong shrinkage of the wound, due to
the presence of dermal muscles. The ready availability of
murine models, together with ease of management and
sampling, may explain their frequent use in such trials.
Monitoring of the healing is most often done bi-weekly at
the same time as the dressings are changed, which prevents
a daily assessment of wound closure. For these reasons, we
chose the Galiano wound model [36] to avoid significant
shrinkage observed on mice and thus slow the closure of
their wound, making it closer to the physiology of human
skin healing. In addition, a larger wound area than usual
(12 mm instead of 6 mm in most protocols) was created
and covered with a transparent dressing in order to carry
out daily measurements of the surface of the wound and
assess the total healing time more precisely.
In this study, we aimed to evaluate, in this optimized
healing model, the effectiveness of injecting a controlled
dose of cultured ASCs, using different criteria such as
wound healing kinetics and skin perfusion. Furthermore, in
order to avoid their dispersion in the subcutaneous tissue,
ASCs were injected in an European Community-approved
(EC labeled) hyaluronic acid gel with added vitamins
and minerals (Cytocare® 532, Revitacare Laboratory,
Saint-Ouen-l’Aumône, France) that we tested for bio-
compatibility, bioavailability and tolerance [37].
Methods
Adipose tissue collection
Surgical residue was harvested according to French reg-
ulations and declared to the Research Ministry (DC n°
2008162) following written informed consent from the
patients.
Method for final product preparation: ASCs in Cytocare® 532
Human SVF was isolated from lipoaspirate obtained
from three randomly chosen healthy volunteers under-
going optimized liposuction [38], using 3 mm cannulae.
Briefly, adipose tissue was digested with collagenase
(0.120U/ml, Roche, Indianapolis, IN, USA) at 37 °C for
30 min and under constant shaking. Digestion was
stopped by adding Dulbecco’s Modified Eagle’s Medium
(DMEM with glutamax, Gibco (Invitrogen, Carlsbad,
CA, USA) containing 10 % fetal calf serum (FCS,
HyClone, Logan, UT, USA). Floating adipocytes were
discarded and cells from the SVF were pelleted, rinsed
with medium, centrifuged (300 g for 5 min. at 20 °C)
and incubated in an erythrocyte lysis buffer for 20 min
at 37 °C. This cell suspension was centrifuged (300 g for
5 min, 20 °C) and cells were counted using the Trypan
blue exclusion method.
A total of 40,000 SVF cells/cm2 were plated and grown
in proliferation medium containing DMEM (Gibco,
Life technologies), HAM-F12 L-Glutamine (Gibco®,
Life technologies, St Aubin, France) (v/v), 10 % FCS
(HyClone), 10 ng/ml basic fibroblast growth factor (FGF2,
Miltenyi Biotec, Paris, France), 10 μg/ml of gentamicin
and 100 UI/ml penicillin (Panpharma, Fougeres, France).
The medium was changed three times a week until 80 %
confluence was reached. At subconfluency, cells were de-
tached with trypsin-0.01 % EDTA (Invitrogen) and centri-
fuged for 10 min at 300 g and amplified in subculture at
4,000 cells/cm2 density (passage 1). At subconfluency, the
cells were trypsinized, counted and cryopreserved in FCS/
DMSO (90/10, v/v) (DMSO, Wak Chemie Medical
GmbH, Steinbach, Germany). Samples were harvested for
all the quality controls described below. On the day of sur-
gery, the cells were thawed, washed, counted, and then
mixed with the vehicle (Cytocare® 532) for injection into
nude mice at a density of 1.106 cells/ml of Cytocare® 532.
Characterization of adipose-derived stem cells
Unless indicated, all chemicals were purchased from
Sigma Aldrich, St. Louis, MO.
Cells were characterized for their phenotype using
flow cytometry. Briefly, after detachment, cells were
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re-suspended in PBS at a concentration of 1-2 million/
mL. Then, 100 μL of this cell suspension were stained in
PBS using FITC-coupled CD45 and PE-coupled CD90,
CD73, CD14, CD34, and HLA-DR antibodies or appropri-
ate isotypic controls (All from BD Biosciences, Le pont de
Claix, France). At least twenty thousand events were ac-
quired with a FACSCanto II cytometer (BD Biosciences,
Le Pont de Claix, France) and analyzed (DIVA software).
The cells were then tested for their ability to differenti-
ate into various mesodermal lineages. For adipogenic
differentiation, confluent cells at passage 1 were induced
using adipogenic medium consisting of DMEM supple-
mented with 10 % of FCS, 10 μg/mL of 3-isobutyl-1-
methylxanthine (IBMX), 100 μM of indomethacin, 1 μM
of dexamethasone and 200 mUI of insulin (Umulin, Lilly
laboratories, Neuilly-sur-Seine, France). After 14 days,
lipid droplets were stained using 0.4 % Oil Red O solu-
tion after 10 % formalin fixation.
For osteogenic differentiation, sub-confluent cells at
passage 1 were induced using a StemPro® osteogenesis
differentiation kit (Gibco®, Life technologies, St Aubin,
France). After three weeks, cells were fixed and stained
with 40 mM Alizarin red (Merck Millipore, Fontenay
sous Bois, France) to visualize calcium deposition.
Chondrogenic differentiation was evaluated using the
high-density pellet culture approach, as previously de-
scribed [39]. Briefly, subconfluent cells at P1 were detached
using trypsin-EDTA, numerated, and 2.5×105 viable ASCs
were centrifuged (300 g, 10 min, two times) in a V-bottom
96-well plate (BD Biosciences, Le Pont de Claix, France) to
form a pellet. The pellets were treated for 28 days with de-
fined chondrogenic medium, which consisted of DMEM-
F12 (4.5 g/L glucose, Life Technologies, St Aubin, France),
1 % of insulin-transferrin-selenium (ITS, Life Technologies,
St Aubin, France), 100 nM dexamethasone, 170 μM L-
ascorbic acid-2-phosphate, 1 mM sodium pyruvate,
350 μM L-proline, 10 ng/mL of transforming growth
factor β3 (TGFβ3, R&D Systems, Minneapolis, MN,
USA) and 50 ng/mL bone morphogenetic protein-2
(BMP-2, InductOs, Wyeth, Taplow, UK).
Proliferation medium was used for each differentiation
control condition. The medium was changed three times
a week.
In vivo experimental protocol in nude mice
The present study was performed in accordance with
the Guide for the Care and Use of Laboratory Animals,
published by the National Institutes of Health (NIH
Publication No. 85–23, revised 1996). All the experimen-
tal procedures were approved by the Ethics Committee
of Lyon I Claude Bernard University (DR-2014-25).
Thirty male, nude, seven-week-old mice were anesthe-
tized with buprenorphine (0.1 mg/kg) and ketamine
(20 mg/ml) and surgery was performed under standard
sterile conditions. One circular, full thickness 12 mm
diameter wound was created on the back of each mouse
and a ring of silicone (Folioxane®, ref FU050M, Nova-
tech, La Ciotat, France) was sutured in place to pre-
vent skin retraction.
During the follow-up, buprenorphine was adminis-
trated intra-peritoneally every day at a dose of 0.1 mg/
kg/day during the first week and 0.05 mg/kg/day during
the second week to avoid suffering. Each wound on each
mouse was injected intradermally with 1 mL of final
product containing 1.106 ASCs (500 μL Cytocare 532
containing 0.5 × 106 cells) around the wound into four
injection sites and the other 500 μL applied onto the
wound surface as previously described [20].
Briefly, one wound was created on each of the 30 mice
randomly divided into three groups: 6 mice in the spon-
taneous healing (SH) group, 12 mice in the vehicle group
(Cytocare® 532), and 12 mice (four per each ASC donor)
in the ASCs group (ASCs in Cytocare® 532).
Tolerance evaluation
Tolerance was assessed by the detection of serious side-
effects (death), observation of the state of the wounds
(oozing, infection), and general monitoring of the animals
through weight gain and finally pain, using the McGill
pain scale [40].
Wound closure measurements
Every day, mice were observed and digital images were
taken. Wound area was measured by tracing the wound
margin and calculating the pixel area using image ana-
lysis software (Adobe Photoshop 7.0).
The wound healing rate was calculated as follows:
100−
Surface of actual non re‐epithelialized zoneð Þ
Surface at D0ð Þ  100
Histological and immunohistochemical analyses
On day 27, the scar tissue was harvested with a rim of
healthy normal tissue. Tissue samples were fixed in 10 %
buffered formalin before embedding in paraffin. For histo-
logical analysis, tissue sections (3 μm) were deparaffinized,
rehydrated and then stained with Masson’s trichrome or
picro-sirius red. Following staining, slides were dehydrated
with graded solutions of ethanol and methylcyclohexane
baths and sealed with Permount mounting medium
(Thermo Fisher Scientific, Saint Aubin, France).
For Masson’s trichrome, stained slides were scanned
with a Mirax Scanner (Zeiss, Marly le Roi, France) and
images were taken using a digital camera (Hitachi HV
F22) and Mirax Scan 150 software (v 1.2, Zeiss). Images
were analyzed using Pannoramic viewer software (v 1.15,
3DHistech, Budapest, Hungary). For picro-sirius red,
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stained slides were observed under polarized light (Leica
DM 2000) and images were taken using a digital camera
(Leica DFC420C) and LAS v4 software (Leica).
For immunohistochemical examination, all the wash-
ing steps consisted of three times 5 min each in PBS
containing 0.2 % Tween 20. Three μm-thick sections
were deparaffinized and rehydrated using methylcyclo-
hexane, graded ethanol and running tap water baths.
Antigens were retrieved using ficin for 10 min at 42 °C
(Digest-All 1 Ficin, Life Technologies, St Aubin, France)
and sections were then cut. Endogenous peroxidase ac-
tivity was inactivated for 20 min with PBS containing
3 % normal goat serum (NGS, Merck Millipore, Fonte-
nay sous Bois, France) and 5 % hydrogen peroxide
(Sigma Aldrich, Saint-Quentin Fallavier, France). After-
wards, non-specific protein binding was avoided by
blocking with PBS containing 5 % NGS. Primary mouse
anti-mouse alpha smooth muscle actin (clone αsm-1,
Leica Microsystems, Nanterre, France) was diluted 1:200
in PBS containing 5 % NGS and applied to the sections
that were incubated overnight at 4 °C in a humid cham-
ber. The sections were then washed and the secondary
antibody (Envision + system HRP labelled polymer anti-
mouse, Dako, Les Ulis, France) was applied for 45 min
at room temperature. After a last washing step, the de-
tected antigens were visualized by incubation with 3,3′-
diaminobenzidine (Liquid DAB+ Substrate Chromogen
System, Dako, Les Ulis, France). Finally, sections were
counterstained with Mayers hematoxylin, and mounted
using Faramount aqueous mounting medium (Dako).
Assessment of skin perfusion
For all the experiments, animals were anesthetized with
isoflurane and then placed in a heated environment to
maintain a stable cutaneous temperature (35.0 ± 0.5 °C)
throughout the measurements. Mice were placed in the
prone position and skin blood flow (SBF) was measured
using a laser Doppler imager (PERISCAN PIM3, Perimed,
Sweden).
SBF was recorded for 1 min and signal analysis was
performed off-line by calculating the average perfusion
on each surface (43 mm2) of interest (PIMSoft software,
Perimed, Järfälla, Sweden).
Assessment of cutaneous microcirculation
To test the cutaneous microcirculation, two experiments
were conducted in the three groups as previously de-
scribed [41, 42]: endothelium-independent vasodilation
in response to sodium nitroprusside (SNP) was evalu-
ated, as well as endothelium-dependent vasodilation in
response to acetylcholine (ACh).
For the experiments, animals were anesthetized by in-
traperitoneal injection of sodium thiopental (65 mg/kg).
The level of anesthesia was determined by testing eye
reflexes and tail pinch. The animals were then settled in
an incubator (MMS, Chelles, France) heated to maintain
a stable cutaneous temperature (35.0 ± 0.5 °C). Mice
were placed in the prone position, followed by a 20 min
resting period to stabilize the blood pressure and cutane-
ous temperature. Tail noninvasive blood pressure (IITC,
Woodland Hills, CA) was recorded before and after the
experiments to verify mean arterial blood pressure
(MABP) stability. At the end of each experiment, the
animals were killed by an overdose of thiopental.
To test endothelium-independent and -dependent re-
sponses, skin blood flow (SBF) was recorded during trans-
cutaneous iontophoresis, using a laser Doppler multifiber
probe (481-1, Perimed) applied to a 1.2 cm2 hairless area
on the back of the animals. Endothelium-independent
response was assessed using cathodal SNP iontophoretic
delivery (67 mmol/L; Nitriate®; SERB, Paris, France) with
the application of a 100 μA current for 20 s. Endothelium-
dependent response was assessed using anodal ACh
iontophoretic delivery (5.5 mmol/L; Sigma, Saint Quentin
Fallavier, France) with the application of a 100 μA current
for 10 s. SNP and ACh were dissolved in deionized water.
SNP- and ACh-induced vasodilator responses are reported
as the maximal percentage increase from baseline in re-
sponse to the iontophoretic delivery of SNP and ACh,
respectively.
Statistical analysis
Statistical analysis was performed using Graphpad Prism 4
software. All the data are expressed as means ± SEM. For
the wound healing rate, unpaired t-tests were carried out
to evaluate statistical significance. For complete wound
closure, the Kruskal-Wallis test was followed by a Dunn’s
multiple comparison test to estimate the significance of
differences for between-group comparisons. For skin
perfusion and assessment of endothelium-independent
and -dependent response experiments, one-way analysis of
variance (ANOVA) was followed by a multiple comparison
test to estimate the significance of differences for between-
group comparisons. Significance was defined at p < 0.05.
Results
ASC characterization
Adipose-derived stem cells (ASCs) were isolated using our
laboratory’s routine method. Briefly, adipose tissue was
collagenase-digested and cells were collected as the stro-
mal vascular fraction (SVF) and grown in proliferation
medium until passage 1 (two subcultures). Cells were
characterized by flow cytometry and displayed a mesen-
chymal stem cell phenotype (Fig. 1a) as more than 98 % of
the cells expressed CD90, CD73, and HLA-ABC and less
than 2 % expressed CD14, HLA-DR, and CD45. Further-
more, these cells were able to differentiate towards adipo-
genic, osteogenic, and chondrogenic lineages, as shown
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by Oil red O, Alizarin red, and Alcian blue staining,
respectively (Fig. 1b).
Animal experiments
Throughout the experiment we had to exclude three
mice for the loss of the ring causing a strong retraction
of the wound and skewing the results except for toler-
ance. Analysis of the effectiveness was performed on 27
wounds: 6 untreated SH controls, 11 with the vehicle
alone (Cytocare® 532), 10 with ASCs in Cytocare® 532.
Tolerance
No serious side effects were observed following treat-
ment. Whatever the treatment, no secondary infection
was identified after the wounds. Only normal exudation
phases were observed for each mouse, more or less late
in the study. No behavioral abnormalities were detected in
the mice with regard to food intake and spontaneous
motor activity. An average 10 % weight gain was observed
during the study period.
Effects of ASCs on the kinetics of skin healing
All wounds had an initial area of around 110 mm2
(radius = 12 mm). Figure 2a shows the representative
digital images of the evolution of wound healing for each
group at 0, 7, 14, and 21 days post-surgery. Figure 2b
shows the percentage of wound healing rate over time
post-surgery. During the first week, no differences were
observed between the different treatments: 20 % of the
wound was re-epithelialized. Then, from the seventh day
post-surgery, a significant acceleration of wound healing
was observed, for all treatments, compared to untreated
Fig. 1 Immunophenotyping and trilineage differentiation of ASC. a ASCs were stained with antibodies and analyzed by flow cytometry. ASCs
expressed markers CD73, CD90, and HLA ABC and were negative for CD45, CD14, and HLA DR. Representative histograms are shown. b ASCs
were cultured in adipogenic, osteogenic or chondrogenic differentiation medium. Cells were fixed and stained with Oil Red O for adipogenesis,
Alizarin red for osteogenesis and Alcian blue for chondrogenesis. Representative images are shown. Scale bar = 100 μm. ASCs adipose-derived
stem cells, CD cluster of differentiation, HLA human leukocyte antigen
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wounds (SH group). By the thirteenth day, there was 85 %
epithelialization with cultured ASCs, 68 % in the vehicle
group and 40 % without treatment.
The time to complete healing was significantly short-
ened after treatment with ASCs (Fig. 2c). Indeed, in the
group treated with ASCs, the number of days to closure
was significantly lower than in the two control groups,
14.6 ± 0.3 days for ASC in Cytocare® 532, 21.2 ± 1.1 (p <
0.001) days without treatment, and 17.4 days ± 0.8 with
Cytocare® 532 alone, p <0.05. Thus, these results show
that treatment with ASCs represents a gain of time to
wound closure of more than six days versus SH and
2.8 days versus vehicle alone.
Histological analysis of scar tissue
Masson’ trichrome staining (Fig. 3) was used to analyze
the overall quality of scarred areas. All the biopsies
presented a good stratified and differentiated epithelium.
The dermis appeared much thinner in the ASC group, with
more homogenous ECM than in the two controls groups,
SH and Cytocare® 532, in which the dermis appeared
less vascularized and more inflammatory. Moreover,
Fig. 2 Influence of ASCs on wound healing kinetics. a After surgery, nude mice were intradermally injected or not with Cytocare® 532 or ASCs.
Representative images are shown for 0, 7, 14, and 21 days post-surgery. Scale bar 5 mm. b Percentage of wound healing was monitored every
day until complete wound closure. Results are expressed as means, with error bars indicating SEM. Statistical analysis was performed using the
unpaired t-test. * p < 0.05, **p < 0.01 and † p < 0.001 compared to spontaneous healing. c Days to complete wound closure were noted. Results
are expressed as means of days needed to reach complete closure and error bars indicate SEM. The Kruskal-Wallis test was followed by Dunn’s
multiple comparison tests to estimate the significance of differences for between-group comparisons. *** p < 0.001 compared to spontaneous
healing. ASCs adipose-derived stem cells
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picro-sirius red staining under polarized light showed
more red collagen fibers in the ASC group than in the two
control groups.
Skin perfusion
Skin perfusion, measured on the scar tissue on day
27, was significantly higher in the ASCs group (ASCs
4.4 ± 0.5 a.u./mm than in the untreated (2.5 ± 0.4 a.u./mm2)
and vehicle 2.8 ± 0.2 a.u./mm2; P < 0.01) groups. There
was no statistical difference between the untreated
and vehicle groups.
Assessment of endothelium-dependent response
In the untreated and vehicle groups, skin blood flow
(SBF) increased in response to iontophoretic delivery
of ACh, corresponding to an endothelium-dependent
Fig. 3 Wound histology after Masson’s trichrome and Picro Sirius red staining. Tissue sections obtained from the wound area at day 27 after cell
injection were stained with Masson’s trichrome (left panel) and Picro Sirius red (right panel). Representative micrographs of wound histological
images are shown. ASCs adipose-derived stem cells
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vasodilation of 33 ± 6 % and 33 ± 3 %, respectively.
The ACh-induced vasodilation observed in the ASCs
group (55 ± 7 %) was significantly higher than in both
the untreated and vehicle groups (P < 0.05).
Assessment of endothelium-independent response
In all groups, SBF increased in response to iontophoretic
delivery of sodium nitroprusside (SNP) and no difference
was observed in the endothelium-independent vasodilation
between groups (untreated 47 ± 13 %, vehicle 51 ± 6 %,
ASCs 44 ± 8 %).
Quantification of dermal capillary density
Immunohistochemistry of αSMA (Fig. 4d) showed no
significant differences between the two control groups,
as the number of total blood vessels in the healed area was
17.33 ± 0.27 and 23.67 ± 0.54 for the SH and Cytocare® 532
groups, respectively (p > 0.05). Although there was no
statistical difference in the vascular density between
ASC-treated and Cytocare 532-treated mice, the ASCs
in Cytocare 532 treatment showed an increase in the
number of blood vessels to 95 ± 9.3.
Discussion
Many treatments using SVF [43, 44] and adipose-derived
stem cells (ASCs) are already in use [45–48] in plastic
and cosmetic surgery. The main problem encountered
with SVF-based therapy is the poor reproducibility of
the outcomes, which might be due to the insufficiency
of ASCs. For this reason, SVF is now often used in
combination with fat in what is known as cell-assisted
lipotransfer (CAL) [45, 49, 50].
In this preclinical study, we demonstrate the tolerance
and therapeutic effectiveness of human cultured ASCs in
a mouse wound model. The cells were intradermally
administered in a skin-protecting and antioxidant nutrient
vehicle, Cytocare® 532, for which the biocompatibility and
bioavailability of ASCs in Cytocare® 532 were previously
shown [37]. In terms of in vivo tolerance, no impact was
noticed on mortality and no infection was observed des-
pite the absence of antibiotics. In all the tested groups, the
pain due to the excisional wound, evaluated on the Mogill
pain scale [40], was controlled by the daily administration
of buprenorphine over the first two weeks.
Evaluation of the therapeutic efficacy of ASCs must
take into account the characteristics of the chosen
wound model in our study. In this model, a Galiano sili-
cone ring was sutured to the edges of the wound to pre-
vent retraction and lengthen the average healing time by
eight days, as previously shown [20, 51, 52]. It is now
considered that the average time for the complete clos-
ure of a 10 mm wound increases from 12 days without,
to 20 days with, a ring [23]. Our results were essentially
the same in the SH group with 21 days for a slightly
larger wound (12 mm), and with an accurate assessment
since the readings were performed frequently. The use
of a transparent dressing greatly improves wound tracking
from both an ethical and a practical point of view as it
permits daily monitoring of the percentage of epitheliali-
zation and the time to complete wound closure without
the need to sacrifice the animal before each observation,
as has been done in some experimental protocols [25]. In
the literature, the assessment of wound closure is usually
performed once or twice per week [23, 53], or sometimes
only once during the entire healing period [54], by re-
moving the dressing after the mice are under anesthesia,
with the additional risk of tearing the newly formed
epithelium, or sacrificing an animal at each observation.
Overall, when considering the main evaluation criter-
ion, i.e., the time for full wound closure, the improve-
ments we have made to the Galiano model include: 1) a
daily reading of re-epithelialization, made possible by the
use of transparent dressings; and 2) increases in the ini-
tial wound surface (12 mm instead of the 6 mm often
practiced) [20, 24]. This greater wound area will increase
the intra-group reproducibility (in this study, the SEM
for the mean time to wound closure ranged from 0.3 %
to 1.1 depending on the group) and the sensitivity of the
model to assess treatments promoting wound healing.
Using this model, the effect of ASCs on wound healing
was shown, by significantly shortening the time to
complete healing by more than six days, when compared
to the SH group (p < 0.001). Overall, these results con-
firm the literature data showing accelerated healing after
administration of ASCs [20, 53]. However, it should be
noted that these studies differ from ours by the choice
of model (see above) and the vehicle, which in some
cases is also not specified. With no need to pull off
dressings, the use of a vehicle [37, 55] to avoid dilution
or loss of ASCs after injection, as well as the daily moni-
toring of healing, we put aside many biased interpreta-
tions and facilitated the experiment.
Our results also suggest that Cytocare® 532, selected as
the vehicle, operates to potentiate the ASC effect. In
fact, its main component, hyaluronic acid [56], a macro-
molecule forming a fundamental part of the extracellular
matrix of the skin, plays a vital role in the healing
process by controlling cell migration and proliferation,
as well as modulating the inflammatory and angiogenic
processes in the early stages of healing, and progressive
tissue remodeling [57–60].
Beyond the healing time criterion, one of the therapy
objectives now being tested in healing models is obtain-
ing a good repair, the closest possible to healthy skin to
prevent recurrence of the wound and the development of
a chronic wound, as often observed in obese and diabetic
patients. Histological aspects of the skin revealed by
Masson’s trichrome staining showed that the treatment
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strongly improved the quality of the dermis which seemed
to be in the remodeling phase in ASC-treated mice, while
still in the proliferative phase with many inflammatory cells
in the SH and Cytocare® 532 groups (Fig. 3, left panel).
Furthermore, picro-sirius red staining highlighted the
presence of type I collagen, as shown by the presence of
red fibers in the healed tissue, whereas the majority of the
fibers observed in the SH and Cytocare® 532 groups were
green, revealing the presence of type III collagen [61, 62].
One of the most important parameters for quality
healing is vascularization. A perfusion defect, whether it
is associated with poorly functioning blood vessels or
low neo-angiogenic levels, leads to a risk of relapse, sus-
tainability of the wound or necrosis. Our results show
that there is no defect in vascular smooth muscle func-
tion (Fig. 4a, b and c), suggesting that the enhanced
endothelial response observed in the ASC groups could
reflect an improved endothelial function within the
wound healed tissue under ASC treatment. An increase
in dermal vascular density (Fig. 4d) could suggest that
ASC treatment could promote angiogenesis during the
wound healing process, which, in turn, could also lead
Fig. 4 Quantitative and functional aspects of blood perfusion in the healed tissue. a Quantification of perfusion at day 27 after surgery was
performed on the healed tissue compared with normal skin using laser Doppler imaging. b Percentage of vasodilation after ACh iontophoresis
and c after SNP iontophoresis in SH-, Cytocare® 532- and ASC-treated mice. d One-way ANOVA was followed by a multiple comparison test to estimate
the significance of differences for between-group comparisons. Significance was defined at P < 0.05 and ** p < 0.01 vs. control. Tissue sections obtained
from the wound area 27 days after cell injection were stained with antibody against alpha smooth muscle actin and blood vessels in the total wound
area were quantified. Representative images of the staining are displayed for each group. The Kruskal-Wallis test was followed by Dunn’s multiple
comparison test to estimate the significance of differences for between-group comparisons. * p < 0.05 compared to spontaneous healing. All data are
expressed as mean ± SEM. Ach acetylcholine, ASCs adipose-derived stem cells, SH spontaneous healing, SNP sodium nitroprusside
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to improved microcirculation and to a reduced wound
healing delay, compared to the control groups. The
potential of ASCs in promoting revascularization has
already been shown [33].
These results suggest that in our wound model, ASCs
can improve perfusion by directly affecting the function
of these vessels or indirectly through a reduction in fi-
brosis and acceleration of the healing process. Overall,
our study shows the therapeutic benefit of ASCs in the
wound healing context and their effect on shortening
the healing period, increasing perfusion. The healing ef-
fect that we observe here is promising for application,
particularly in cases of chronic wounds that sometimes
lead to a therapeutic impasse that could become life-
threatening for some patients.
Conclusions
The tolerance to, and efficacy of, cryopreserved ASCs, to
rapidly obtain the complete closure of a wound by in-
creasing the maturation of the skin and its blood perfu-
sion shows their therapeutic benefit in the wound
healing context, reinforcing our in vitro results using a
three-dimensional model demonstrating the potential of
ASCs to obtain a complete stratified and differentiated
epidermis [63].
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